Horizon Pharma disclosed that it received a civil investigative demand today from the United States Department of Justice pursuant to the Federal False Claims Act regarding assertions that certain of its payments to pharmacy benefit managers were potentially in violation of the Anti-Kickback Statute. The CID requests certain documents and information related to payments to pharmacy benefit managers, pricing and patient assistance program regarding Deuxis, Vimovo and Pennsaid 2%, Horizon disclosed in a regulatory filing. It added, “We intend to cooperate with the investigation. While we believe that our payments and programs are compliant with the Anti-Kickback Statute, no assurance can be given as to the timing or outcome of the DOJ’s investigation, or that it will not result in a material adverse effect on our business.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.